LIDDS participates in LSX World Congress and ERLIG Therapeutic Oligo meetings
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company will participate in two important events in the coming weeks. Firstly, the LSX World Congress, taking place in London between 3 and 4 May 2023. Secondly, ELRIG Therapeutic Oligo and European Chemical Biology symposium, taking place at AstraZeneca in Gothenburg between 9 and 11 May 2023.
LIDDS’s CEO Anders Månsson, and CSO Matthew Lindon will participate in the LSX World Congress, which is physically organized in London, UK. The LSX meeting is focused on partnering, strategy & investment for life science executive leaders. The meeting provides LIDDS with more opportunities for both collaboration and partner discussions. LIDDS’s attendance will be in conjunction with our on-going partnership with Alira Health to drive forward our business development activities.
LIDDS’s CSO, Matthew Lindon will attend ELRIG Therapeutic Oligo and European Chemical Biology symposium, taking place at AstraZeneca in Gothenburg, where he has been accepted to present a poster on LIDDS’s Nanoimod project. This poster showcases LIDDS’s work to successfully formulate an oligonucleotide therapeutic in NanoZolid® and highlights the pre-clinical work supporting progressing this asset into Phase I clinical studies.